In brief: Peplin, Bone Medical, Probiomics, BioDiem
Monday, 01 August, 2005
Peplin (ASX:PEP) has suspended its shares from the ASX's official quotation in the lead-up to an announcement.
Bone Medical (ASX:BNE) has appointed BIO-IB as financial advisors to assist with a potential capital raise targeting US institutional investors expected to take place later this year.
Taylor Collison intends to underwrite a $1 million placement of new fully paid ordinary shares in Probiomics (ASX:PCC). A total of 12,500,000 shares will be issued at $0.08 per share and the funds from the placement will be used for working capital.
BioDiem (ASXBDM) has received its second US$1 million milestone payment under its US$8m licence agreement with Akzo Nobel's Nobilon in the development of its novel intranasal flu vaccine.
Widespread resistance to common antibiotics is increasing: WHO
Increasing resistance to essential antibiotics poses a growing threat to global health, with one...
Dopamine helps our brains to let go of memories
In a discovery that could reshape how we think about memory, researchers at Flinders University...
Vaccine for elephant herpesvirus found to be safe
The vaccine could prevent deadly elephant endotheliotropic herpesvirus in calves — the...
